MedTrace Logo

Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

NCT05905380 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-06-18

No results posted yet for this study

Summary

Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Conditions

  • COVID-19 Convalescent Plasma Treatment

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05905380 on ClinicalTrials.gov